Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

BIB vs. SHPAX: which is better?

Bottom line

BIB vs SHPAX: the short answer

BIB (ProShares Ultra Nasdaq Biotechnology) and SHPAX (Health & Biotechnology Portfolio) are both etfs.

But BIB is far broader, holding 267 positions to 29 for SHPAX, so beyond the top names it adds exposure SHPAX doesn't have.

BIB is cheaper at 0.95% vs 3% — a difference of $205 a year per $10,000 invested.

Over five years, SHPAX returned +3.1% a year vs −1.0% for BIB (reporting dates differ).

SHPAX has a front-end sales load of up to 5.75%; the other does not.

Updated Nov 19, 2026

BIB vs SHPAX side by side

BIBSHPAX
TypeETFMutual fund
Fund familyProSharesSaratoga Advantage
CategoryTechnology SectorTechnology Sector
Expense ratio0.95%3%
Annual cost per $10k$95$300
10-yr cost on $10k (prospectus)$1,401$3,702
Max front loadNone5.75%
12b-1 fee——
1-yr return+59.3%−5.5%
5-yr return (annualized)−1.0%+3.1%
10-yr return (annualized)+1.4%+4.1%
Best quarter+56.2%+15.0%
Worst quarter−42.7%−13.0%
Net assets (fund)$73.7M$10.5M
Number of holdings26729
Portfolio turnover29%22%
Returns as ofDec 31, 2025Dec 31, 2024

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearBIBSHPAXDifference
2024−10.0%+0.3%−10.3%
2023−1.3%−0.4%−0.9%
2022−28.6%+2.0%−30.7%
2021−5.9%+16.7%−22.6%
2020+39.7%+3.6%+36.1%
2019+45.5%+16.2%+29.3%
2018−24.4%−5.5%−18.9%
2017+40.8%+12.0%+28.8%
2016−44.2%−2.0%−42.3%

Source: Fund prospectus bar charts

Holdings overlap

6 of BIB's top 25 holdings also appear in SHPAX's top 25.

Shared top holdings
HoldingBIBSHPAX
Gilead Sciences, Inc.4.66%3.94%
Vertex Pharmaceuticals, Inc.4.65%3.36%
Amgen, Inc.4.48%5.04%
Regeneron Pharmaceuticals, Inc.3.21%3.93%
United Therapeutics Corp.1.22%6.17%
Incyte Corp.0.97%2.89%

Source: SEC Form N-PORT

BIB top 10

  1. N/a — 7.35%
  2. ProShares GENIUS Money Market ETF — 6.80%
  3. Gilead Sciences, Inc. — 4.66%
  4. Vertex Pharmaceuticals, Inc. — 4.65%
  5. Amgen, Inc. — 4.48%
  6. N/a — 3.94%
  7. N/a — 3.26%
  8. Regeneron Pharmaceuticals, Inc. — 3.21%
  9. N/a — 2.62%
  10. Alnylam Pharmaceuticals, Inc. — 2.01%

SHPAX top 10

  1. Cardinal Health Inc — 6.44%
  2. Jazz Pharmaceuticals Plc — 6.19%
  3. United Therapeutics Corp — 6.17%
  4. Amgen Inc — 5.04%
  5. Mckesson Corp — 4.90%
  6. Lantheus Holdings Inc — 4.64%
  7. Exelixis Inc — 4.55%
  8. Novartis Ag — 4.50%
  9. Cencora Inc — 4.33%
  10. Gilead Sciences Inc — 3.94%

FAQ

What is the difference between BIB and SHPAX?
BIB (ProShares Ultra Nasdaq Biotechnology) and SHPAX (Health & Biotechnology Portfolio) are both etfs. But BIB is far broader, holding 267 positions to 29 for SHPAX, so beyond the top names it adds exposure SHPAX doesn't have.
Which is cheaper, BIB or SHPAX?
BIB has the lower expense ratio (0.95%).
Should I own both BIB and SHPAX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.